R Retreatment in 1st Relapsed DLBCL
NCT00980304
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
OTHER
Sponsor class
Conditions
Lymphomas
Interventions
DRUG:
Rituximab
Sponsor
Shanghai Jiao Tong University School of Medicine